These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37473799)

  • 21. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Key hepatic signatures of human and mouse nonalcoholic steatohepatitis: A transcriptome-proteome data meta-analysis.
    Pyo JJ; Choi Y
    Front Endocrinol (Lausanne); 2022; 13():934847. PubMed ID: 36267572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
    Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
    World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.
    Xu G; Wang YM; Ying MM; Chen SD; Li ZR; Ma HL; Zheng MH; Wu J; Ding C
    Clin Mol Hepatol; 2021 Apr; 27(2):329-345. PubMed ID: 33465844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis.
    Semba T; Nishimura M; Nishimura S; Ohara O; Ishige T; Ohno S; Nonaka K; Sogawa K; Satoh M; Sawai S; Matsushita K; Imazeki F; Yokosuka O; Nomura F
    BMC Gastroenterol; 2013 Jul; 13():120. PubMed ID: 23875831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of liquid fructose/sucrose in regulating the hepatic transcriptome in a high-fat Western diet model of NAFLD.
    Luo Y; Woodie LN; Graff EC; Zhang J; Fowler S; Wang X; Wang X; O'Neill AM; Greene MW
    J Nutr Biochem; 2023 Feb; 112():109174. PubMed ID: 36280127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.
    Alshawsh MA; Alsalahi A; Alshehade SA; Saghir SAM; Ahmeda AF; Al Zarzour RH; Mahmoud AM
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urea cycle dysregulation in non-alcoholic fatty liver disease.
    De Chiara F; Heebøll S; Marrone G; Montoliu C; Hamilton-Dutoit S; Ferrandez A; Andreola F; Rombouts K; Grønbæk H; Felipo V; Gracia-Sancho J; Mookerjee RP; Vilstrup H; Jalan R; Thomsen KL
    J Hepatol; 2018 Oct; 69(4):905-915. PubMed ID: 29981428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis.
    Zhang X; Shen J; Man K; Chu ES; Yau TO; Sung JC; Go MY; Deng J; Lu L; Wong VW; Sung JJ; Farrell G; Yu J
    J Hepatol; 2014 Dec; 61(6):1365-75. PubMed ID: 25048951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2.
    Ye D; Yang K; Zang S; Lin Z; Chau HT; Wang Y; Zhang J; Shi J; Xu A; Lin S; Wang Y
    J Hepatol; 2016 Nov; 65(5):988-997. PubMed ID: 27266617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis.
    Magee N; Ahamed F; Eppler N; Jones E; Ghosh P; He L; Zhang Y
    Liver Res; 2022 Dec; 6(4):238-250. PubMed ID: 36864891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.